Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFOL-03: Rinatabart Sesutecan vs Investigator's Choice in Endometrial Cancer After Platinum and PD-(L)1 Therapy
jRCT2031250494Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in endometrial cancer (EC) (2 arms), sponsored by Genmab. Primary endpoints: Progression-free Survival (PFS) per RECIST v1.1 by Blinded Independent Central Review and Overall Survival (OS). Started Nov 2025; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031250494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250494.